Razpis: Programme to Accelerate Clinical Trials (PACT)

Funding for biomarker-based, proof-of-concept pilot clinical trials relevant to Alzheimer's disease, other dementias and cognitive ageing.

datum: 21.09.2017

kategorija: novice

Slika_tablete

Financer: Alzheimer's Drug Discovery Foundation

Vrednost projekta: 2.920.000,00 EUR

Upravičenost kandidatov: javne in zasebne pravne osebe, profitne in neprofitne organizacije, vključno z akademskimi ustanovami in biotehnološkimi podjetji, ne glede na lokacijo

Rok za prijavo: 17. 11. 2017

Prijava: preko spletne strani

---

Founded in 1998 by co-chairman Leonard A. and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) provides funding to leading scientists who are conducting the most promising, innovative Alzheimer's drug research worldwide.

The ADDF aims to plug the translational funding gap between basic research and later stage drug development by funding promising preclinical drug discovery and biomarker development programmes relevant to Alzheimer's disease, other dementias and cognitive ageing.

The ADDF's Programme to Accelerate Clinical Trials (PACT) scheme is intended to increase the number of innovative drugs tested in humans at the proof of concept stage for Alzheimer's disease. This programme will fund biomarker-based, proof-of-concept pilot clinical trials for Alzheimer's through three mechanisms:

Terms and Conditions

Programme areas of particular interest include: